Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

Trial Details

NCT ID
NCT06993844
Phase
PHASE1 / PHASE2
Sponsor
Ensem Therapeutics
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • ETX-636 dose escalation
  • ETX-636 dose escalation in combination with fulvestrant
  • ETX-636 dose expansion in combination with fulvestrant
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • San Francisco, California, United States|37.77493,-122.41942
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Metastatic or locally advanced and unresectable solid tumor that has progressed on or after at least one available therapy.
  • Tumor harboring an activating PIK3CA mutation detected in either tumor tissue or ctDNA.
  • At least 1 measurable lesion or evaluable disease per RECIST v1.1.
  • An ECOG performance status score of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →